公开(公告)号：EP3310774A1

公开(公告)日：2018-04-25

申请号：EP16731666.0

申请日：2016-06-15

申请人： Novartis AG

发明人： TOURE, Bakary-Barry ,  CHEN, Zhuoliang ,  FORTANET, Jorge Garcia ,  JOUK, Andriana ,  KARKI, Rajesh ,  LAMARCHE, Matthew J. ,  LIU, Gang ,  PALERMO, Mark G. ,  PEREZ, Lawrence Blas ,  SARVER, Patrick James ,  SHULTZ, Michael David ,  YU, Bing

IPC分类号： C07D401/14 ,  C07D401/04 ,  C07D471/10 ,  C07D491/107 ,  C07D498/10 ,  A61K31/506 ,  A61K31/537 ,  A61P35/00 ,  A61P9/00 ,  A61P19/00 ,  A61P21/00 ,  A61P25/28

CPC分类号： C07D401/14 ,  C07D401/04 ,  C07D471/10 ,  C07D491/107 ,  C07D498/10

摘要： in which Y1, Y2, Y3, R1, R2, R4a, R5b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.